Mark D. Girgis, MD
- Surgical Oncology
About
Link to Dr. Girgis' complete CV >
Dr. Girgis is an Assistant Professor of Surgery at the David Geffen School of Medicine at UCLA and Director of Robotic Surgery. He also has a joint appointment at the West LA VA Medical Center. His interests include robotic and minimally invasive approaches to surgical oncology and more specifically on gastric and pancreaticobiliary diseases in his clinical practice as well as research endeavors. He received advanced training in robotic surgery and surgical oncology in his fellowship at the University of Pittsburgh. He is one member of the group of pancreaticobiliary surgeons at UCLA that provide the highest level of care for their patients and leads the gastroesophageal tumor multidisciplinary program. He is committed to the improvement of cancer care through innovative technological advancements as well as ground breaking research. His research endeavors focus on developing novel small molecules targeting pancreas and gastric cancer for radioligand therapy and is part of a multidisciplinary group that collaborates on a variety of projects centered on developing new therapies for cancer patients.
Languages
Education
Medical Board Certifications
Fellowship
Residency
Internship
Degree
Recognitions
-
Super doctors, Southern California, 2024
- Super Doctors® Southern California, 2023, 2024
- Super Doctors® Southern California Rising Stars 2021
- Super Doctors® Southern California Rising Stars 2020
- See More
Related Clinical Trials
Locations
UCLA Agi Hirshberg Center for Pancreatic Diseases
Hospital Affiliations
Ronald Reagan UCLA Medical Center
UCLA Santa Monica Medical Center
Medical Services
Areas of Focus
Research
Interests
- Targeting pancreas and gastric cancer with novel peptides used for radioligand therapy
- Genomic analysis of pancreatic, gastric, and biliary tumors
Publications
- Girgis MD, King J, Steve J, Zenati MS, Novak S, Winters SB, Bartlett DL, Zureikat A, Zeh HJ, Hogg ME. Long Term Oncologic Outcomes After Robotic Resections Are Not Inferior to Open for Pancreas Cancer. Submitted
- Girgis MD, Zenati MS, Steve J, Zureikat A, Bartlett DB, Zeh HJ, Hogg ME. Robotic Approach Mitigates the Risk of Wound Infection and Perioperative Morbidity in Obese Patients Following Pancreaticoduodenectomy. Submitted
- Liu K, Wang MW, Lin WY, Phung DL, Girgis MD, Wu AM, Tomlinson JS, Shen C. Molecular Imaging Probe Development using Microfluidics. Current Organic Synthesis. 2011 Aug 8 (4): 473-487
- Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Anti-CA19-9 Diabody as a PET Imaging Probe for Pancreas Cancer. J Surg Res. 2011 Oct;170(2):169-78
- Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. CA19-9 as a Potential Target for Radiolabeled Antibody-based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imag. July 2011 (2011): 1-9
- Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res. 2011 Nov 7;1(1):24
- Girgis MD, Federman N, McCabe KE, Rochefort M, Wu AM, Nagy JO, Denny C, Tomlinson JS. An Engineered Anti-CA19-9 Cys-Diabody for PET Imaging of Pancreas Cancer and Targeting of Polymerized Liposomal Nanoparticles. J Surg Res. 2013 Nov;185(1):45-55
- Rochefort MM*, Girgis MD*, Ankeny J, Tomlinson JS. Metabolic Exploitation of the Sialic Acid Biosynthetic Pathway to Generate Site-Specifically Labeled Antibodies. Glycobiology. 2014 Jan;24(1):62-9 *denotes co-first authors
- Rochefort MM, Girgis MD, Knowles S, Ankeny J, Bergara F, Wu AM, Tomlinson JS. A Mutated Anti CA19-9 scFv-Fc for Positron Emission Tomography of Human Pancreatic Cancer Xenografts. Molecular Imaging and Biology. 2014 Oct;16(5):721-9
- Ankeny JS†, Court CM†, Hou S, Li Q, Song M, Wu D, Chen JF, Lee T, Lin M, Sho S, Rochefort MM, Girgis MD, Wainberg ZA, Muthusamy VR, Watson R, Donahue TR, Hines OJ, Reber HA, Graeber TG, Tseng HR, Tomlinson JS († Denotes Co-First Authorship). Circulating Tumor Cells as an Adjunctive Biomarker for Diagnosis and Staging in Pancreatic Cancer. British Journal of Cancer. 2016 Jun 14; 114 (12):1367-75
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- L.A. Care
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.
Recognitions
- Super Doctors® Southern California, 2023, 2024
- Super Doctors® Southern California Rising Stars 2021
- Super Doctors® Southern California Rising Stars 2020
- Super Doctors® Southern California Rising Stars 2019
- Leonard Tow Humanism in Medicine 2018
- Golden Scalpel Teaching Award in Surgery 2018
- ACS Jameson L. Chassin Professionalism in General Surgery Award, Top 10 Finalist
- Overall Best Resident Award (UCLA)
- GI ASCO Merit Award
- AAS Outstanding Resident Research Award
- Outstanding Medical Student Teaching Award